FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2488968211> ?p ?o ?g. }

• W2488968211 abstract "Purposes: The close connection between imbalanced immunity and tumor progression has been increasingly recognized, and a number of inhibitors for blocking immune inhibitory checkpoints have been established to improve the anti-tumor immunity in cancer patients. However, clinical responses are limited to a part of the treated patients. We previously identified FSTL1, which is significantly secreted from Snail+ metastatic tumor cells, as a key effector molecule in the cancer-caused immune suppression and dysfunction. FSTL1 generates and expands pluripotent mesenchymal stem cells (MSCs), which are able to generate various immunoregulatory cells and functionally impaired CD8-low T cells, and also to induce de novo tumor dissemination into bone marrow. FSTL1 also directly confers higher invasiveness on tumor cells (EMT induction). To prevent the FSTL1-caused vicious circulation for tumor progression, we attempted to establish anti-FSTL1 blocking mAbs. Results: We generated chicken/mouse chimeric anti-FSTL1 mAbs, which specifically recognized human and mouse FSTL1. The anti-FSTL1 mAb significantly suppressed tumor proliferation and invasion, MSC induction in mouse bone marrow cells, and Treg induction in human PBMCs in vitro as compared to the control group. When bone metastatic melanoma models (C57BL/6 mice implanted with snail-transduced B16-F10 melanoma cells both subcutaneously and intravenously) were intraperitoneally injected with the anti-FSTL1 mAb (10 mg/kg) on Day 5 (when tumor metastasis was already observed in bone marrow) and Day 10 after tumor implantation, the FSTL1-caused events were inhibited, and tumor-specific CD8+ T cells with higher CTL activities were generated, resulting in significant suppression of subcutaneous tumor growth and bone metastasis in the treated mice as compared to those of the control mice. At least in the same models, conventional immune checkpoint inhibitors including anti-CTLA4, anti-PD1, and anti-PDL1 mAbs failed to improve the anti-tumor immunity, and rather promoted bone metastasis because of no reduction of regulatory cells, particularly the MSCs in the treated mice. Conclusions: These results suggest that blocking FSTL1 reprograms and properly induces anti-tumor immunity by switching the tumor-supportive immune directivity to the active mode against cancer. Our anti-FSTL1 mAb having totally different molecular mechanisms from the conventional ones may be a promising therapeutics as a next generation of “immune checkpoint inhibitors” for radically correcting cancer-manipulated immunity in clinical settings. Citation Format: Chie Kudo-Saito, Masayoshi Toyoura, Yuji Shoya, Akiko Ishida, Ryoko Kon. Blocking FSTL1 reprograms cancer-caused abnormal immunity. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3224." @default.
• W2488968211 created "2016-08-23" @default.
• W2488968211 creator A5020222750 @default.
• W2488968211 creator A5055346366 @default.
• W2488968211 creator A5062310825 @default.
• W2488968211 creator A5079729022 @default.
• W2488968211 creator A5080930445 @default.
• W2488968211 date "2016-07-15" @default.
• W2488968211 modified "2023-09-25" @default.
• W2488968211 title "Abstract 3224: Blocking FSTL1 reprograms cancer-caused abnormal immunity" @default.
• W2488968211 doi "https://doi.org/10.1158/1538-7445.am2016-3224" @default.
• W2488968211 hasPublicationYear "2016" @default.
• W2488968211 type Work @default.
• W2488968211 sameAs 2488968211 @default.
• W2488968211 citedByCount "0" @default.
• W2488968211 crossrefType "proceedings-article" @default.
• W2488968211 hasAuthorship W2488968211A5020222750 @default.
• W2488968211 hasAuthorship W2488968211A5055346366 @default.
• W2488968211 hasAuthorship W2488968211A5062310825 @default.
• W2488968211 hasAuthorship W2488968211A5079729022 @default.
• W2488968211 hasAuthorship W2488968211A5080930445 @default.
• W2488968211 hasConcept C121608353 @default.
• W2488968211 hasConcept C126322002 @default.
• W2488968211 hasConcept C142724271 @default.
• W2488968211 hasConcept C154317977 @default.
• W2488968211 hasConcept C167672396 @default.
• W2488968211 hasConcept C198826908 @default.
• W2488968211 hasConcept C202751555 @default.
• W2488968211 hasConcept C203014093 @default.
• W2488968211 hasConcept C2776090121 @default.
• W2488968211 hasConcept C2777658100 @default.
• W2488968211 hasConcept C2779013556 @default.
• W2488968211 hasConcept C2779256057 @default.
• W2488968211 hasConcept C2779341262 @default.
• W2488968211 hasConcept C2780007613 @default.
• W2488968211 hasConcept C502942594 @default.
• W2488968211 hasConcept C55493867 @default.
• W2488968211 hasConcept C71924100 @default.
• W2488968211 hasConcept C86803240 @default.
• W2488968211 hasConcept C8891405 @default.
• W2488968211 hasConcept C90375314 @default.
• W2488968211 hasConceptScore W2488968211C121608353 @default.
• W2488968211 hasConceptScore W2488968211C126322002 @default.
• W2488968211 hasConceptScore W2488968211C142724271 @default.
• W2488968211 hasConceptScore W2488968211C154317977 @default.
• W2488968211 hasConceptScore W2488968211C167672396 @default.
• W2488968211 hasConceptScore W2488968211C198826908 @default.
• W2488968211 hasConceptScore W2488968211C202751555 @default.
• W2488968211 hasConceptScore W2488968211C203014093 @default.
• W2488968211 hasConceptScore W2488968211C2776090121 @default.
• W2488968211 hasConceptScore W2488968211C2777658100 @default.
• W2488968211 hasConceptScore W2488968211C2779013556 @default.
• W2488968211 hasConceptScore W2488968211C2779256057 @default.
• W2488968211 hasConceptScore W2488968211C2779341262 @default.
• W2488968211 hasConceptScore W2488968211C2780007613 @default.
• W2488968211 hasConceptScore W2488968211C502942594 @default.
• W2488968211 hasConceptScore W2488968211C55493867 @default.
• W2488968211 hasConceptScore W2488968211C71924100 @default.
• W2488968211 hasConceptScore W2488968211C86803240 @default.
• W2488968211 hasConceptScore W2488968211C8891405 @default.
• W2488968211 hasConceptScore W2488968211C90375314 @default.
• W2488968211 hasLocation W24889682111 @default.
• W2488968211 hasOpenAccess W2488968211 @default.
• W2488968211 hasPrimaryLocation W24889682111 @default.
• W2488968211 hasRelatedWork W1620660089 @default.
• W2488968211 hasRelatedWork W1811130292 @default.
• W2488968211 hasRelatedWork W1881476874 @default.
• W2488968211 hasRelatedWork W2076312642 @default.
• W2488968211 hasRelatedWork W2094895057 @default.
• W2488968211 hasRelatedWork W2097432512 @default.
• W2488968211 hasRelatedWork W2168458474 @default.
• W2488968211 hasRelatedWork W2318496421 @default.
• W2488968211 hasRelatedWork W2331081870 @default.
• W2488968211 hasRelatedWork W2332404561 @default.
• W2488968211 hasRelatedWork W2332703482 @default.
• W2488968211 hasRelatedWork W2399273302 @default.
• W2488968211 hasRelatedWork W2425731878 @default.
• W2488968211 hasRelatedWork W2735925363 @default.
• W2488968211 hasRelatedWork W2741392634 @default.
• W2488968211 hasRelatedWork W2954101464 @default.
• W2488968211 hasRelatedWork W3013531700 @default.
• W2488968211 hasRelatedWork W3133438406 @default.
• W2488968211 hasRelatedWork W3137354412 @default.
• W2488968211 hasRelatedWork W3181386875 @default.
• W2488968211 isParatext "false" @default.
• W2488968211 isRetracted "false" @default.
• W2488968211 magId "2488968211" @default.
• W2488968211 workType "article" @default.